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Coronavirus, an outsized family of viruses, noted to 
cause diseases which range from simple cold to more 
severe diseases like severe SARS (2002 – 2004) and 
MERS (2012) (WHO, 2020). A much recent, Novel 
coronavirus (COVID-19) caused by similar family of 
viruses is an infectious disease primarily associated 
with symptoms ranging from mild to severe life-
threatening conditions particularly pneumonia.1 First 
ever case was recorded in Wuhan city of China during 
the ending month of 2019 and has been associated with 
myriad of fungal, bacterial and viral co-infections. 
While the pathophysiology is still under investigation, 
new indicative manifestations and complications of 
the same continue to be identified and described in 
medical literature.2 
  
Since the beginning of this pandemic, a large number 
of studies have centered on quick diagnosis, 
advancement, and redirection of new treatment plans. 
In many cases, it was found that SARS-CoV-2 is 
something much more than a respiratory disorder. 
Significant degrees of endogenous substances 
delivered by this infection are capable of producing 
changes and disturbances influencing the target 
tissues. They even go past the hindrances of protection 
of the innate tissue immunity, reaching the systemic 
level through hematogenous transmission.3 This 




constant chronic inflammatory process that can 
promptly lead to fibrosis of lungs, loss of function, 
pulmonary degeneration, oxygenation impairment, 
culminating the delayed hypoxic state, anoxemia and 
hypoxemia and ultimately leading to death. Patients 
having metabolic diseases such as diabetes mellitus, 
autoimmune diseases, cardiopulmonary diseases, or 
patients undergoing chemotherapy, corticotherapy or 
radiotherapy have a higher danger of death.4 
 
Apart from arrhythmias, thrombo-embolic 
complications, cardiac injury (acute), and strokes, 
secondary opportunistic infections including white 
fungus (candidiasis) and black fungus (mucormycosis) 
are much prevalent. 
  
MUCORMYCOSIS 
Zycomycosis or Phycomycosis was first described by 
Paltauf in 1885 and later changed to Mucormycosis by 
Baker (American pathologist) in 1957 due to severe 
form of infection caused by Rhizopus. Fungi which 
belong to the order Mucorales are distributed into six 
families and all are responsible for cutaneous and deep 
infections.5 Head of the fungal pathogenesis group at 
the institute for medical research, Julie Djordjevic 
described it as a “NATURE’S DECAYER”.6   
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60% of mucormycosis cases in humans and 90% of the 
Rhino-orbital-cerebral form. It is usually uncommon 
but can occur as an opportunistic severe fungal 
infection in people who have altered immune system 
and affects the sinuses, lungs and brain leading to life 
threatening conditions in cancer patients, diabetic 
patients, or people suffering from HIV or AIDS. These 
pathogens are commonly present in soil along with 
association with decaying organic matter, such as 
rotten wood, compost piles, or leaves. It is commonly 
transmitted through inhalation of these fungal spores.7 
 
PATHOGENESIS 
Both mononuclear and polymorphonuclear 
phagocytes of ordinary hosts kill Mucorales by the 
creation of metabolites and the cationic peptides 
defensins. Clinical proof exhibits that these phagocytes 
are the significant host defense system against 
mucormycosis. For instance, neutropenic and 
phagocytic dysfunctional patients are at expanded 
danger of creating mucormycosis. The capacity of 
phagocytes to engulf these fungi by their oxidative and 
nonoxidative components is disabled by 
hyperglycemia (diabetes mellitus) and acidosis. 
Furthermore, corticosteroid treatment influences the 
capacity of broncho alveolar phagocytes to prevent 
germination of the spores in vitro or after in vivo 
contamination initiated by intranasal inoculation. The 
specific components by which ketoacidosis, diabetes, 
or steroids impede the capacity of these phagocytes 
stay obscure.5  
 
CLINICAL PRESENTATION 
The clinical sign of this disease (mucormycosis)  is 
vascular invasion leading to  tissue necrosis  and 
thrombosis. Mucormycosis practically consistently 
happens in people with defects in host defense 
mechanism and/or potentially with increased available 
serum iron, albeit uncommon cases have been 
accounted for in evidently normal hosts. This disease 
is determinedly progressive and results in death except 
if treatment with a careful surgical debridement and 
antifungal drugs is started instantly.8  
 
According to the clinical presentation and the 
involvement of a specific anatomic site, mucormycosis 
has been divided into at least six clinical classifications:  
(1)pulmonary, (2)disseminated, (3)cutaneous, 
(4)gastrointestinal, (5)rhinocerebral, and 
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Sinusitis along with clogging of the nasal tract with 
blackish or bloody mucus emission from the nose is the 
main indication of mucormycosis. Blackish 
discoloration on the bridge of the nose, along with pain 
on one side of the face, cheekbone and lack of 
sensation and buldging of the involved area are 
observed.  Abnormal clotting of blood tissue 
thrombosis, damage or injury to the skin and/or 
necrosis of the dermal cells are also seen. Impairment 
of respiratory functions, pain in chest, excessive build-
up of fluid in lungs and  haemoptysis are also 
observed.9 
 
Blood clots with blocked vessels, blindness and nerve 
damage prove mucormycosis is deadly if not treated. 
Due to its rare nature, the exact mortality is unknown 
but an overall estimate is roughly  around 45%. The 




The exact time for the presentation of this disease in 
covid patient is usually around third week of onset of 
its symptoms. Physical examination, swab test, 
followed by tissue biopsy and radiographic imaging 
(CT or MRI) are used to detect the extent of it. 
 
Specific investigations include 1. Non-contrast  
 
Table 1. Relationship between predisposing 
conditions and site of infection5 
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computed tomography scan of the sinuses particularly 
paranasal sinuses (NCCT PNS) to detect the bony 
erosion; 2. High resolution computed tomography 
chest (HRCT chest) and CT Angiography and 3. MRI of 
the brain for better delineation of CNS involvement.  
 
Diagnosis includes 1. KOH staining and microscopy, 
followed by histopathology of the debrided tissues and 
culture; 2. Matrix-assisted laser desorption/ionization-
time of flight (MALDI-TOF) mass spectrometry if 
available and 3. Presence of ribbon like aseptate 
hyphae (5-15 μ), branching at right angles.11       
                                         
PREVENTION AND TREATMENT 
 Ensuring proper oral hygiene, wearing face shields and 
masks, maintaining hand hygiene, regular changing of 
masks and avoiding unnecessary visits to crowded and 
dirty or polluted environments are main prevention 
goals in preventing any co-morbidity related to covid. 
  
For prevention of mucormycosis, it is important to 
control hyperglycemia, discontinue any 
immunomodulating drug and reduce the use of 
steroids. Maintaining the adequate systemic 
hydration, normal saline (IV) infusion followed by 
amphotericin B and anti-fungal therapy for atleast 4-6 
weeks is required. In case of diabetic and covid 
patients, it is very much important to control 
hyperglycemia and regularly monitor blood glucose 
levels during and after Covid treatment. Steroid use 
must be judicious with correct dosage, timing and 
duration.6 
     
The major treatment part includes antifungals but 
depending upon the severity, surgery is the end 
treatment. Mucormycosis can cause damage to upper 
jaw and even eye. Loss of functions including facial 
aesthetics, chewing, swallowing and loss of self-esteem 
can lead to the detrimental effect on the patients 
mental health. Hence management of covid patients 
with mucormycosis approach involving team of 
professionals such as microbiologist, internal medicine 
specialist, ENT specialist, ophthalmologist, dental 
surgeon (oral and maxillofacial surgeon for 
reconstruction) and others.2  
 
METHOD 
A systematic search of literature was done in the 
electronic database of SCOPUS, PUBMED, 
COCHRANE and EMBASE, using keywords SARS CoV-
2, COVID 19 and MUCORMYCOSIS. Details of articles 
that reported confirmed and suspected patients with 
mucormycosis, so far till June 2021 were retrieved. 
Characteristic of the subjects were analysed on various 
endpoints and outcomes (table 2). 
 
DISCUSSION 
Though been an extremely rare case (mucormycosis) 
in healthy individual, severe immunocompromised 
patients predispose it. Uncontrolled diabetes mellitus 
with or without diabetic ketoacidosis, organ 
transplantation, hematological and various other 
malignancies, corticosteroid therapy, prolonged 
neutropenia, iron overload, voriconazole prophylaxsis 
for transplantation patients, AIDS, and malnutrition 
are main predisposing factors. Nose, sinuses, CNS, 
orbit, lungs, GIT, skin, joints, jaw bone are the areas 
involved, though rhino-orbital-cerebral (ROC) form is 
more common among all. ROC form is frequently 
observed in association with uncontrolled diabetes and 
diabetic ketoacidosis, whereas pulmonary involvement 
is often seen in patients suffering from neutropenia, 
and hematological malignancies while GIT 
involvement is seen in malnourished individuals.26 
 
Eosinophilic necrosis, thrombosis, and giant cell 
invasion of the underlying area is the main 
pathological symptom of mucormycosis. Its gold 
standard criteria for clinical diagnosis was given by 
Smith and Krichner in 1950 which included: black and 
necrotic turbinate, easily misdiagnosed for crusted, 
dried blood. Blood tinged nasal discharge with facial 
pain, soft peri-orbital swelling, ptosis and proptosis of 
the eye with a multiple number of cranial nerve 
palsies.27   
 
Prakash et al.28 (2019) and Patel et al.29( 2020) have 
found that rhino-orbital-cerebral was the utmost 
presentation  which was followed by pulmonary and 
cutaneous type in patients with uncontrolled 
hyperglycaemia. Systematic review by John et al 
reported 41 cases in people with COVID-19 and 
diabetes was found in 93% of the cases and 88% were 
on steroid therapy. These findings were consistent 
with that of Awadesh et al, where they found that 80% 
of the mucormycosis cases were hyperglycemic and 
76.3%  received corticosteroids.30 No studies are 
available that compared patients of mucormycosis 
with/without confounding factors. 
  
LIMITATION 
Various limitations were seemed to be found while 
conducting this systematic review, using case reports 
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Mehta et al12 Sep,2020 Mumbai 1 Diabetes Confirmed Nasal, Orbit Death 
Hanley et al13 Oct,2020 UK 1 Nil Confirm, Autopsy Lung Death 
Placik et al14 Nov,2020 USA 1 Nil Confirmed Lung Death 
Monte Junior 
et al15 
Nov,2020 Brazil 1 Nil Confirmed GIT Death 
Zurl et al16 Jan,2021 Austria 2 Leukemia Confirmed Bone Death 
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Garg et al20 May,2021 Chandigarh 1 Diabetes Confirmed Lung Improved 
 






























Jun,2021 USA 1 Diabetes Confirmed Lung Improved 







2021 USA 1 Nil Confirmed Nasal, Orbit Improved 






and series which are subjected to publication biases 
with considerable diversity of the reported cases. The 
active and recovered SARS CoV-2 cases and its 
correlation  to the onset of mucormycosis is difficult 
due to the less sensitivity of confirmatory reverse 
transcriptase polymerase chain reaction. Lack of 
denominator value, does not allow the real estimation 
of the incidence of mucormycosis.  
 
CONCLUSION  
COVID-19 is found to be associated with significant 
incidence of opportunistic bacterial and fungal 
infections due to immune dysfunction. Additional due 
to steroid therapy, broad spectrum antibiotics, 
monoclonal antibodies lead to exaggeration   of   pre-
existing   fungal   diseases. While  still, there is no major 
outbreak, physicians should be aware of the possibility  
Table 2. Characteristic of the subjects reported by various authors analysed on the basis of  various endpoints and outcomes 
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of invasive opportunistic infections in patients with 
SARS CoV-2 and pre-existing risk factors. Use of 
therapeutic agents should be monitored to achieve the 
effect at the minimal dose and for the momentary 
duration for maximum efficacy. Thus, it becomes very 
much essential to make the judicious use of drugs and 
reducing major outbreak with decreased mortality. 
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